Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline

Folia Pharmacologica Japonica

Volumn 122, Issue 2, 2003, Pages 141-150

  Hanada, Mitsuharu ^a   Noguchi, Toshihiro ^a   Murayama, Takao ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Amrubicin hydrochloride; Calsed; DNA topoisomerase II inhibitor; Lung cancer; Malignant lymphoma

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; GYRASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER GRAFT; CANCER SURVIVAL; CELL GROWTH; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NEUTROPENIA; NONHUMAN; NUDE MOUSE; PHASE 2 CLINICAL TRIAL; REVIEW; STOMACH CARCINOMA; XENOGRAFT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SMALL CELL; CELL DIVISION; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DEPRESSION, CHEMICAL; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; NEUTROPENIA; TUMOR CELLS, CULTURED;

EID: 0042656888     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.141     Document Type: Review

References (29)

1. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18:185-197.
2. Ishizumi K, Ohashi N, Tanno, N. Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem. 1987;52:4477-4485.
3. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res. 1989;80:69-76.
4. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res. 1998;89:1061-1069.
5. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res. 1998;89:1229-1238.
6. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res. 1998;89:1067-1073.
7. Limonta M, Biondi A, Giudici G, et al. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. Cancer Chemother Pharmacol. 1990;26:340-342.
8. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol. 1992;30:51-57.
9. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res. 1989;80:77-82.
10. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res. 1998;89:1055-1060.
11. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985;54:665-697.
12. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989;989:163-177.
13. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351-375.
14. Drake FH, Hofmann GA, Mong SM, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 1989;49:2578-2583.
15. Soørensen BS, Sinding J, Andersen AH, Alsner J, Jensen PB, Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. J Mol Biol. 1992;228:778-786.
16. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA. 1992;89:3025-3029.
17. Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated mammalian DNA topoisomerase II. Cancer Res. 1986;46:2021-2026.
18. Wolverton JS, Danks MK, Granzen B, Beck WT. DNA topoisomerase II immunostaining in human leukemia and rhadomyosarcoma cell lines. Cancer Res. 1992;52:4248-4253.
19. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners podophyllotoxin including VP-16-213 and VM 26: a quantitative structure-activity relationship. Biochemistry. 1984;23:1183-1188.
20. Jensen PB, Soørensen BS, Demant EJF, et al. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anidine in human small cell lung cancer cell lines and topoisomerase II-mediated DNA cleavage. Cancer Res. 1990;50:3311-3316.
21. Jensen PB, Jensen PS, Demant EJF, et al. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 1991;51:5093-5099.
22. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis (2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991;51:4909-4916.
23. Feld R, Wierzbicki R, Walde PLD, et al. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol. 1992;10:297-303.